{"entity":{"id":"china-vbp-nrdl","kind":"term","name":"China National Reimbursement Drug List negotiation and volume-based procurement","aka":["NRDL","National Reimbursement Drug List","NRDL negotiation","volume-based procurement","VBP","4+7 pilot","national volume-based procurement","NHSA negotiation"],"tldr":"China's two price levers: an annual negotiation, since 2017, in which a new cancer drug wins national reimbursement only by cutting its price, often by half or more, and tenders since 2018 in which generic makers bid for guaranteed hospital volumes, collapsing prices of off-patent drugs.","summary":"China, administrative schemes of the National Healthcare Security Administration (NHSA), created in 2018 to unify the country's public insurance funds. The National Reimbursement Drug List (NRDL) had been updated rarely until 2017; the first national price negotiation for listing was held that year, a dedicated oncology negotiation in 2018 added seventeen cancer drugs at an average reduction of more than half, and negotiations have run every year since. Volume-based procurement began with the '4+7' pilot tender in eleven cities in December 2018 and was extended nationwide in 2019, with successive rounds covering hundreds of molecules. Primary text: the NHSA publishes each year's list and tender results in Chinese; the Wikipedia article on the NHSA covers the institutions.\n\nHow they work: for the NRDL, a company submits a dossier and a confidential price offer, health economists and budget-impact experts set a reference, and a one-round negotiation decides whether the drug is listed for two years at the agreed price, which then applies across the country; drugs conditionally approved months earlier can be reimbursed the following January. For volume-based procurement, manufacturers of generics that have passed quality consistency evaluation bid for a share of the promised annual volume of public hospitals, and the lowest bids win with cuts often above 50 percent; later rounds included biosimilars and insulin.\n\nWhy it matters for oncology and the arguments: PD-1 inhibitors were listed at a small fraction of US prices, giving hundreds of millions of people access, and generic imatinib, gefitinib and capecitabine became cheap; multinational companies have accepted deep cuts for volume or declined to list. Critics point to quality and supply concerns among winning bidders, to hospital pressure to use tendered products, and to the effect of confidential Chinese prices on international reference pricing; the NHSA in 2024 began a separate commercial insurance list for high-priced innovative drugs to address the complaint that the negotiation squeezed innovation.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/National_Healthcare_Security_Administration","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/National_Healthcare_Security_Administration"}],"tags":["law","cn"],"related":["hta","drug-price-transparency","china-drug-administration-law","inflation-reduction-act","amnog","biosimilar","global-oncology-access","who-essential-medicines","financial-toxicity"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib"],"companies":[],"institutions":["nhsa","nmpa-cde"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/china-vbp-nrdl/","neighbours":{"term":[{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/"},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/"},{"id":"china-drug-administration-law","kind":"term","name":"China Drug Administration Law (2019) and expedited pathways","route":"/terms/china-drug-administration-law/"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/"},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/"}],"technology":[{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"institution":[{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/"},{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}